Clinical trials: PET-CT
Mandibular Osteoradionecrosis
USE OF 18FDG PET-CT TO PREDICT THE RESPONSE OF MANDIBULAR OSTEORADIONECROSIS TO THE PENTOCLO PROTOCOL WITH DOCUMENTED ANTIBIOTHERAPY
This study is created in order to refine and reduce the duration between the medical and surgical therapeutic sequences (when the surgery is necessary) in these fragile patients knowing that conventional radiological changes can…
- Trial name
- PENTOTEP (NCT04826445)
- Testing
- Data collection
- Where
- France
- Volunteers
- 75 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Advanced Cancers
A Pilot, Exploratory, Non-Randomized Study of PET/CT With the Investigational Agent [18F] Fluciclatide to Correlate With Response to Anti-Cancer Therapy
The goal of this clinical research study is to find out if using the tracer (liquid used in imaging scans) [18F]fluciclatide in positron emission tomography / computed tomography (PET/CT) scans will help researchers learn more…
- Trial name
- NCT02193672
- Testing
- [18F] Fluciclatide, PET/CT Scan, Phone Calls
- Sponsor
- M.D. Anderson Cancer Center
Inflammatory Bowel Diseases
Positron Emission Tomography (PET)-Computed Tomography (CT) in Inflammatory Bowel Disease (IBD)
The main hypothesis is that PET-CT will be a valuable diagnostic tool in diagnosing and evaluating treatment for IBD.
- Trial name
- NCT00205062
- Testing
- PET-CT
- Where
- United States
- Sponsor
- University of Wisconsin, Madison
Breast Cancer
Molecular Imaging of Breast Cancer With Breast PET/CT
This study is a feasibility study to determine if a combined breast PET/CT scanner can image malignant functional activity while determining anatomical structure in the same clinical setting for patients with breast cancer.
- Trial name
- NCT00584753
- Testing
- Positron emission tomography and computed tomography
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Granulomatosis With Polyangiitis (Wegener's)
Assessing Granulomatosis With Polyangiitis Activity: 18F-FDG PET/CT vs BVAS v3
The goal of this observational study is to quantify activity and extent of disease in patients with GPA using 18F-FDG PET/CT. The main questions it aims to answer are: Sensitivity of 18 F-FDG PET/CT in patients with GPA?…
- Trial name
- NCT07712172
- Testing
- 18F-FDG, 18F-FDG PET/CT
- Where
- India
- Volunteers
- 31 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Adrenal Tumor
18FDG PET Textural Indices in Adrenal Lesion
Tumors are characterized by a great heterogeneity. Characterizing this intra-tumor heterogeneity is a major challenge in oncology to improve the therapeutic management and move towards personalized medicine adapted to each…
- Trial name
- ImpactTexture (NCT03469102)
- Where
- France
- Volunteers
- 53 people
- Sponsor
- University Hospital, Brest
Solid Tumors
Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors
This project is driven by clinical needs and focuses on the mucin (MUC) family, key glycopeptide antigens involved in mediating immune evasion in solid tumors. We selected multiple members of this family as research subjects.
- Trial name
- NCT07529002
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking University Cancer Hospital & Institute
Cancer
68Ga-grazytracer PET/CT of Tumor Responses to Immunotherapy
This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the safety and clinical predictive value of 68Ga-grazytracer in subjects with solid tumor or lymphoma receiving immunotherapy.
- Trial name
- NCT05000372
- Testing
- 68Ga-grazytracer
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Peking University Cancer Hospital & Institute
WHO Grade 3 Glioma, WHO Grade 4 Glioma
An Investigational Scan (Ga-68 PSMA-11 PET/CT) for Detection of Disease Recurrence or Progression in Patients With Glioma
This clinical trial evaluates whether gallium-68 (Ga-68) prostate specific membrane antigen (PSMA)-11 positron emission tomography (PET)/computed tomography (CT) imaging is useful in differentiating between disease that has come…
- Trial name
- NCT06444412
- Testing
- Computed Tomography, Electronic Health Record Review, Ga 68 PSMA-11
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Mayo Clinic
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial
This phase II trial tests how well an imaging procedure called fludeoxyglucose F-18 (FDG) positron emission tomography/computed tomography (PET/CT) works in predicting response to standard of care chemotherapy prior to surgery in…
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Invasive Breast Carcinoma
- Trial name
- NCT05710328
- Testing
- Chemotherapy, Computed Tomography, Fludeoxyglucose F-18
- Where
- 102 sites in United States, Puerto Rico
- Volunteers
- 235 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Positron-Emission Tomography
68Ga-NOTA Evans Blue PET/CT in Patients With Lymphatic System Related Diseases
To evaluate the potential usefulness of 68Ga-NOTA Evans Blue (68Ga-NEB) positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and efficacy assessment in lymphatic system related diseases.
- Trial name
- NCT05140083
- Testing
- 68Ga-NOTA Evans Blue
- Where
- China
- Volunteers
- 80 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage II Prostate Cancer AJCC v8
Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer
This randomized phase III trial studies the success rate of definitive radiation therapy (dRT) for prostate cancer (PCa) with or without planning based on PSMA PET.
- Conditions
- Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8
- Trial name
- PSMA-dRT (NCT04457245)
- Testing
- Computed Tomography, Fluorine F 18 DCFPyL, Positron Emission Tomography
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Tumor, Solid, FAPI, PET/CT, Metastasis
Comparison of 68Ga-DOTA-FAPI-46 and 68Ga-DOTA-2P(FAPI)2 PET/CT in Patients With Various Types of Cancer
To evaluate the potential usefulness of 68Ga-DOTA-2P(FAPI)2 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various types of cancer, compared with 68Ga-DOTA-FAPI-46…
- Trial name
- NCT04941872
- Testing
- 68Ga-DOTA-FAPI-46 and 68Ga-DOTA-2P(FAPI)2 PET/CT
- Where
- China
- Volunteers
- 7 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Cancer Diagnosis, Diagnostic Techniques and Procedures
Comparison of PET/CT vs. PET/MRI Using 2 Radiopharmaceuticals
This clinical trial studies how well positron emission tomography (PET)/computed tomography (CT) works compared to PET/magnetic resonance imaging (MRI) in evaluating patients with cancer.
- Conditions
- Cancer Diagnosis, Diagnostic Techniques and Procedures, Diagnostic Imaging
- Trial name
- NCT03125629
- Testing
- F-18 FDG, Ga-68-DOTA-TATE, Positron Emission Tomography / Computed Tomography (PET/CT) Scan
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Stanford University
Primary Aldosteronism Due to Aldosterone Producing Adenoma, Primary Aldosteronism
11C-Metomidate PET/CT for Endocrine Hypertension and Characterisation of Adrenal Tumours
10% of patients with hypertension potentially have the treatable condition - primary aldosteronism (PA). This is caused by either bilateral adrenal disease (~40%), managed with lifelong medications; or unilateral disease (~60%)…
- Conditions
- Primary Aldosteronism Due to Aldosterone Producing Adenoma, Primary Aldosteronism, Adrenal Tumors
- Trial name
- NCT06100367
- Testing
- 11C-Metomidate PET/CT imaging at Clinical Imaging Research Centre
- Where
- 7 sites in Singapore
- Volunteers
- 97 people
- Sponsor
- Changi General Hospital
Hepatocellular Carcinoma (HCC)
PSMA PET for the Staging and Management of Hepatocellular Carcinoma
This prospective, single-center study evaluates the clinical utility of F18-Piflufolastat (PSMA) PET/CT when added to conventional cross-sectional imaging for patients with suspected or confirmed hepatocellular carcinoma (HCC).
- Trial name
- NCT07019844
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- VA Office of Research and Development
Hematological Malignancies
A Study Evaluating the Value of 68Ga-Pentixafor PET Imaging in the Staging of Hematological Tumor, and Comparing It with 18F-FDG PET/CT Imaging
This is a prospective, open-label, single-center clinical study targeting hematological malignancies. 120 patients with a confirmed by pathology of non-Hodgkin's lymphoma or myeloma were included.
- Trial name
- NCT06834412
- Testing
- 68Ga-Pentixafor and 18F-FDG PET/CT Scan
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Xijing Hospital
Prostatic Neoplasms
18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer
PyL, also known as [18F]DCFPyL, is a second-generation fluorinated prostate-specific membrane antigen (PSMA) targeted PET imaging agent.
- Trial name
- NCT03824275
- Testing
- 18F- DCFPyL PET/CT
- Where
- United States
- Volunteers
- 129 people
- Sponsor
- Columbia University
Solid Tumor, Positron-Emission Tomography(PET)
[68Ga]Ga-NOTA-SNA002 (PD-L1 PET Tracer) for PET/CT in Patients With Solid Tumors
The purpose of this study is to evaluate the safety of [68Ga]Ga-NOTA-SNA002 and investigate the uptake of [68Ga]Ga-NOTA-SNA002 in patients with solid tumors.
- Trial name
- NCT05490264
- Testing
- [68Ga]Ga-NOTA-SNA002
- Where
- China
- Volunteers
- 20 people
- Sponsor
- SmartNuclide Biopharma
Renal Cell Carcinoma, Kidney Cancer
Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody
This is a multicenter Phase III study to demonstrate the diagnostic utility of 124I-cG250 PET/CT pre-surgical imaging in patients with operable renal masses.
- Trial name
- NCT00606632
- Testing
- 124-Iodine-cG250 (124I-cG250), CT
- Where
- 14 sites in United States
- Volunteers
- 226 people
- Sponsor
- Heidelberg Pharma AG
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.